Shire PLC (SHP) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of Shire PLC (LON:SHP) have received a consensus rating of “Buy” from the twenty analysts that are presently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is GBX 5,323.33 ($74.64).
A number of research firms have recently issued reports on SHP. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a GBX 5,300 ($74.31) price objective on shares of Shire in a report on Monday, October 30th. Shore Capital reiterated a “buy” rating on shares of Shire in a report on Monday, January 15th. Liberum Capital cut their price objective on Shire from GBX 4,400 ($61.69) to GBX 4,200 ($58.89) and set a “hold” rating for the company in a report on Tuesday, October 24th. Barclays reiterated an “equal weight” rating and issued a GBX 4,000 ($56.09) price objective on shares of Shire in a report on Monday, October 30th. Finally, Deutsche Bank reiterated a “buy” rating on shares of Shire in a report on Monday, December 11th.
In other Shire news, insider Dominic Blakemore acquired 165 shares of the company’s stock in a transaction on Tuesday, December 19th. The stock was acquired at an average price of GBX 3,790 ($53.14) per share, for a total transaction of £6,253.50 ($8,768.23).
COPYRIGHT VIOLATION NOTICE: This article was reported by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/shire-plc-shp-receives-consensus-recommendation-of-buy-from-brokerages/1857696.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.